Body composition and weight changes after ivacaftor treatment in adults with cystic fibrosis carrying the G551 D cystic fibrosis transmembrane conductance regulator mutation: A double-blind, placebo-controlled, randomized, crossover study with open-label extension

Barry, 2014, Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease, Chest, 146, 152, 10.1378/chest.13-2397 Davies, 2013, Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation, Am J Respir Crit Care Med, 187, 1219, 10.1164/rccm.201301-0153OC McKone, 2014, Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: A phase 3, open-label extension study (PERSIST), Lancet Respir Med, 2, 902, 10.1016/S2213-2600(14)70218-8 Ramsey, 2011, A CFTR potentiator in patients with cystic fibrosis and the G551D mutation, N Engl J Med, 365, 1663, 10.1056/NEJMoa1105185 Edgeworth, 2017, Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment, Clin Sci (Lond), 131, 2037, 10.1042/CS20170995 Flume, 2018, Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor, J Cyst Fibros, 17, 83, 10.1016/j.jcf.2017.06.002 Rowe, 2014, Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis, Am J Respir Crit Care Med, 190, 175, 10.1164/rccm.201404-0703OC Yen, 2013, Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis, J Pediatr, 162, 530, 10.1016/j.jpeds.2012.08.040 Sainath, 2019, Italian and North American dietary intake after ivacaftor treatment for Cystic Fibrosis Gating Mutations, J Cyst Fibros, 18, 135, 10.1016/j.jcf.2018.06.004 Stallings, 2018, Energy balance and mechanisms of weight gain with ivacaftor treatment of cystic fibrosis gating mutations, J Pediatr, 201, 229, 10.1016/j.jpeds.2018.05.018 King, 2014, Loss of fat-free mass over four years in adult cystic fibrosis is associated with high serum interleukin-6 levels but not tumour necrosis factor-alpha, Clin Nutr, 33, 150, 10.1016/j.clnu.2013.04.012 Sermet-Gaudelus, 2003, Insulin-like growth factor I correlates with lean body mass in cystic fibrosis patients, Arch Dis Child, 88, 956, 10.1136/adc.88.11.956 Bailey, 2020, Effect of CFTR modulators on anthropometric parameters in individuals with cystic fibrosis: An evidence analysis center systematic review, J Acad Nutr Diet, 10.1016/j.jand.2020.03.014 Alvarez, 2016, Body composition and lung function in cystic fibrosis and their association with adiposity and normal-weight obesity, Nutrition, 32, 447, 10.1016/j.nut.2015.10.012 Ionescu, 2003, Hidden depletion of fat-free mass and bone mineral density in adults with cystic fibrosis, Chest, 124, 2220, 10.1378/chest.124.6.2220 King, 2010, Fat-free mass depletion in cystic fibrosis: Associated with lung disease severity but poorly detected by body mass index, Nutrition, 26, 753, 10.1016/j.nut.2009.06.026 Earthman, 2015, Body composition tools for assessment of adult malnutrition at the bedside: A tutorial on research considerations and clinical applications, JPEN J Parenter Enteral Nutr, 39, 787, 10.1177/0148607115595227 Peleg, 2018, Antibiotic exposure and interpersonal variance mask the effect of ivacaftor on respiratory microbiota composition, J Cyst Fibros, 17, 50, 10.1016/j.jcf.2017.08.002 Bosy-Westphal, 2013, What makes a BIA equation unique? Validity of eight-electrode multifrequency BIA to estimate body composition in a healthy adult population, Eur J Clin Nutr, 67, S14, 10.1038/ejcn.2012.160 Madeira, 2013, Normal weight obesity is associated with metabolic syndrome and insulin resistance in young adults from a middle-income country, PloS One, 8, e60673, 10.1371/journal.pone.0060673 Narayanan, 2017, Adherence to therapies in cystic fibrosis: A targeted literature review, Expert Rev Respir Med, 11, 129, 10.1080/17476348.2017.1280399 Hubert, 2018, Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp-CFTR mutation after 1 and 2 years of treatment with ivacaftor in a real-world setting, J Cyst Fibros, 17, 89, 10.1016/j.jcf.2017.07.001 Turck, 2016, ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis, Clin Nutr, 35, 557, 10.1016/j.clnu.2016.03.004 van der Haak, 2020, Highlights from the nutrition guidelines for cystic fibrosis in Australia and New Zealand, J Cyst Fibros, 19, 16, 10.1016/j.jcf.2019.05.007 McDonald, 2020, Academy of Nutrition and Dietetics: 2020 Cystic Fibrosis Evidence Analysis Center Evidence-based Nutrition Practice Guideline, J Acad Nutr Diet, 10.1016/j.jand.2020.03.015 Harindhanavudhi, 2020, Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: A single-center analysis, J Cyst Fibros, 19, 139, 10.1016/j.jcf.2019.10.004 Franssen, 2008, Obesity and the lung: 5. Obesity and COPD, Thorax, 63, 1110, 10.1136/thx.2007.086827 Wilson, 2017, The effect of ivacaftor CFTR gene-potentiating therapy on cytokine levels in CF patients with the G551D mutation, J Cyst Fibros, 16, S83, 10.1016/S1569-1993(17)30437-X Cheah, 2015, Cessation of pancreatic enzyme replacement therapy (PERT) after initiation of therapy wtih ivacaftor - A case series, J Cyst Fibros, 14, S51, 10.1016/S1569-1993(15)30165-X Heijerman, 2019, Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial, Lancet, 394, 1940, 10.1016/S0140-6736(19)32597-8 Middleton, 2019, Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del Allele, N Engl J Med, 381, 1809, 10.1056/NEJMoa1908639 Beaumesnil, 2011, Ginies JL Body composition analysis in patients with cystic fibrosis. Comparison of 3 methods: Dual energy x-ray absorptiometry, bioelectrical impedance analysis, and skinfold measurements, Arch Pediatr, 18, 370, 10.1016/j.arcped.2011.01.008 Charatsi, 2016, Bioelectrical impedance in young patients with cystic fibrosis: Validation of a specific equation and clinical relevance, J Cyst Fibros, 15, 825, 10.1016/j.jcf.2016.05.004 Alicandro, 2015, Estimating body composition from skinfold thicknesses and bioelectrical impedance analysis in cystic fibrosis patients, J Cyst Fibros, 14, 784, 10.1016/j.jcf.2015.07.011 King, 2005, Body composition assessment in adults with cystic fibrosis: Comparison of dual-energy x-ray absorptiometry with skinfolds and bioelectrical impedance analysis, Nutrition, 21, 1087, 10.1016/j.nut.2005.04.005 Ziai, 2014, Agreement of bioelectric impedance analysis and dual-energy X-ray absorptiometry for body composition evaluation in adults with cystic fibrosis, J Cyst Fibros, 13, 585, 10.1016/j.jcf.2014.01.006